Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 5/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14290008 | 1.00 | DPP8 (0.48) | DPP8DPP7GAASMN1; SMN2KAT8 | |
| SCHEMBL14813701 | 0.89 | ALDH1A1 (0.43) | DPP8DPP7GAASMN1; SMN2KAT8 | |
| SCHEMBL8280193 | 0.88 | GAA (0.43) | DPP8DPP7GAASMN1; SMN2NOS3 | |
| SCHEMBL14813915 | 0.85 | GNAI3 (0.39) | DPP8DPP7GAASMN1; SMN2DPP4 | |
| SCHEMBL17831911 | 0.83 | — | — | |
| SCHEMBL29531291 | 0.82 | ALOX5 (0.38) | DPP8DPP7GAASMN1; SMN2EPHX2 | |
| SCHEMBL14272694 | 0.82 | DPP8 (0.49) | DPP8DPP7GAAEPHX2ALDH1A1 | |
| SCHEMBL8229381 | 0.82 | DPP8 (0.46) | DPP8DPP7EPHX2TACR3 | |
| SCHEMBL17002124 | 0.82 | DPP8 (0.46) | DPP8DPP7EPHX2TACR3 | |
| SCHEMBL8424182 | 0.82 | DPP8 (0.46) | DPP8DPP7EPHX2TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160311817-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311817-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORA, RORB | DPP8 3843/4885DPP7 4196/4885GAA 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.